Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
The Prostate|February 6, 2008
The UGT2B17 gene deletion is not associated with prostate cancer riskMats Olsson, Sara Lindström, Benjamin Häggkvist, et al.
European Journal of Clinical Investigation|January 9, 2013
Testosterone challenge and androgen receptor activity in relation to UGT2B17 genotypesLena Ekström, Luca Cevenini, Elisa Michelini, et al.
Pharmacogenomics|October 24, 2014
Effect of UGT2B7 -900G>A (-842G>A; rs7438135) on morphine glucuronidation in preterm newborns: results from a pilot cohortMaja Matic, Elisabeth Norman, Anders Rane, et al.
Basic & Clinical Pharmacology & Toxicology|February 1, 2006
Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patientsArzu Gunes, Ugur Coskun, Cem Boruban, et al.
European Journal of Clinical Pharmacology|February 12, 2009
SFINX-a drug-drug interaction database designed for clinical decision support systemsYlva Böttiger, Kari Laine, Marine L Andersson, et al.
Pharmacogenetics|May 7, 2004
Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteersJulia Kirchheiner, Mike Ufer, Ev-Charlotte Walter, et al.
Blood|June 25, 2008
The largest prospective warfarin-treated cohort supports genetic forecastingMia Wadelius, Leslie Y Chen, Jonatan D Lindh, et al.
The Journal of Clinical Endocrinology and Metabolism|August 19, 2007
The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in menCharlotte Swanson, Dan Mellström, Mattias Lorentzon, et al.
Plos Genetics|March 21, 2009
A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin doseFumihiko Takeuchi, Ralph McGinnis, Stephane Bourgeois, et al.
Pageof 12